

The inherent problem of pooling: increased false-negative rates

Yair Daon^{1,2}, Amit Huppert^{2,3}, and Uri Obolski^{1,2}

¹*Porter School of the Environment and Earth Sciences, Tel Aviv University, Tel Aviv, Israel*

²*School of Public Health, Tel Aviv University, Tel Aviv, Israel*

³*The Gertner Institute for Epidemiology and Health Policy Research, Tel Hashomer, Israel*

December 2, 2020

Abstract

Background: Pooling is a popular strategy for increasing SARS-CoV-2 testing throughput. A common pooling scheme is Dorfman pooling: test N individuals simultaneously. If the first test is positive — retest each individual.

Methods: Using a probabilistic model, we analyze the false-negative rate (i.e. the probability of a negative result for an infected individual) of Dorfman pooling. Our model is conservative in that it ignores sample dilution effects, which can only worsen pooling performance.

Results: We show that one can expect a 60-80% increase in false-negative rates under Dorfman pooling, for reasonable parameter values. On average, when separate testing misses, e.g., ten infected individuals — Dorfman pooling misses more than sixteen.

Discussion: In most pooling schemes, identifying an infected individual requires positive results in multiple tests and hence substantially increases false-negative rates. It is an inherent shortcoming of pooling schemes and should be kept in mind by policy makers.

1 Introduction

RT-PCR testing is a key component in breaking transmission chains and mitigating the COVID-19 pandemic. As such, the need for large-scale testing has resulted in development of pooling schemes of RT-PCR tests [1, 3, 4, 6, 7]. One such popular scheme is Dorfman pooling [1, 2]: Select N individuals and perform a single RT-PCR test on their combined (“pooled”) samples. If the pooled test yields a positive result — test each individual separately. The throughput efficiency of Dorfman pooling has been demonstrated empirically [1]. However,

when test error rates are taken into consideration, a sharp increase in false-negative rates can be expected.

It is important to distinguish three types of false-negative events when performing pooling. For convenience, we follow a single *infected* individual, henceforth referred to as "Donald". A *single test's* false-negative is the event of a negative result upon testing Donald separately, i.e., in a RT-PCR test without pooling. The probability of such an event is denoted P_{fn} . A *pooled* false-negative occurs when a pooled test containing Donald's sample (and other samples) yields a negative result, i.e., the pooling fails to detect at least one positive result. Lastly, a *scheme* false-negative results occurs when an entire pooling scheme fails to identify Donald as infected. Our goal is to calculate Dorfman's scheme false-negative rate. Or: what is the probability of Dorfman pooling not identifying Donald as infected?

2 Methods

2.1 Probabilistic Assumptions

We assume two pathways for a positive pooled test result: Viral RNA from an infected individual is correctly amplified; or, some testing error occurs, which causes an erroneous amplification. We ignore cross-reactivity with other Coronaviruses, which is negligible [10]. We assume a homogeneous and disconnected population (each individual is infected independently and with equal probability). For simplicity, we do not take into account sample dilution, since it can only further increase false-negative rates [1].

2.2 A simplistic approximation

For Dorfman's scheme to yield a false-negative result, Donald has to test negative in *either* the single *or* the pooled test. If the infection prevalence is low, it is likely that Donald is the only infected individual in the pool. In this case, the false-negative probability of a pooled test equals the single test false-negative rate. See Section 2.3 for a precise calculation. The probability that Donald tests positive in *both* single and pooled test is then $(1 - P_{\text{fn}})^2$. Hence, the entire scheme's false-negative rate is approximately the complement — $1 - (1 - P_{\text{fn}})^2$.

2.3 Calculation of Dorfman's scheme false-negative rate

Denote the prevalence of infection in the (tested) population q . As before, P_{fn} denotes the single RT-PCR test's false-negative rate. We also denote P_{fp} the probability of introducing contaminated RNA in the pooling process (which may cause a false-positive). By our assumptions, a pool containing Donald's sample and $N - 1$ other samples will yield a *negative* result if all of the following occur:

- No contaminant RNA is introduced into the pooled samples. A false-positive does not occur, with probability $1 - P_{\text{fp}}$.

- The amplification process fails for Donald’s sample. A false-negative occurs, with probability P_{fn} .
- The amplification process fails for the other $N - 1$ samples. For a single sample, the probability of being amplified is the prevalence of SARS-CoV-2 in the tested population q , multiplied by the true-positive rate. But the true-positive rate is the complement of P_{fn} , namely $1 - P_{\text{fn}}$, hence the probability of amplification is $q(1 - P_{\text{fn}})$. For $N - 1$ such samples, the probability of *not* being amplified is $(1 - q(1 - P_{\text{fn}}))^{N-1}$.

The pooled false-negative probability for Donald is simply the product of the terms above. Hence:

$$\begin{aligned}\mathbb{P}(\text{pool is positive}) &= 1 - \mathbb{P}(\text{pool false-negative}) \\ &= 1 - (1 - P_{\text{fp}})P_{\text{fn}}(1 - q(1 - P_{\text{fn}}))^{N-1}.\end{aligned}\tag{1}$$

If the pooled test yields a positive result, Donald is tested separately. We assume such a simple procedure poses no risk of introducing contaminant RNA. Therefore, the separate test yields a positive result with probability $1 - P_{\text{fn}}$.

We calculate the probability that Donald is mistakenly identified as not infected — the scheme’s false-negative rate — denoted P_{sfn} below. To *correctly* identify Donald as infected, both pooled and separate tests have to yield a positive result. Thus, the scheme’s false-negative rate P_{sfn} is the complement of the product of the two previous terms:

$$\begin{aligned}P_{\text{sfn}} &:= 1 - \mathbb{P}(\text{correctly identify Donald as infected}) \\ &= 1 - (1 - P_{\text{fn}}) [1 - P_{\text{fn}}(1 - P_{\text{fp}})(1 - q(1 - P_{\text{fn}}))^{N-1}].\end{aligned}\tag{2}$$

2.4 Comparison metric

The single test false-negative P_{fn} and scheme false-negative rate P_{sfn} are compared via:

$$E_{\text{rel}} := \frac{P_{\text{sfn}} - P_{\text{fn}}}{P_{\text{fn}}} \cdot 100.\tag{3}$$

E_{rel} is the percentage increase in the pooling scheme false-negative rate, relative to the single test false-negative rate.

3 Results

To get a sense of the scheme’s false-negative rate, we first plug in $P_{\text{fn}} = 0.2$ [5,8–12] for the single test’s false-negative rate in the simplistic approximation of Section 2.2. We get that Dorfman’s scheme false-negative rate is approximately $1 - (1 - 0.2)^2 = 0.36$. This figure, compared to the single test’s false-negative rate P_{fn} , amounts to $E_{\text{rel}} = 80\%$. Such an increase is an inevitable consequence of




Figure 1: Relative increase in Dorfman pooling false-negative rates E_{rel} . Color represents the relative percentage increase in the scheme false-negative rates relative to the single test false-negative rates, P_{fn} . The disease prevalence, q , is varied on the x-axis, while the single test false-negative rate is varied on the y-axis. Note that Pool size, N , was chosen according to q as in [1].

the fact that, for Donald to be identified as infected, he needs to test positively in two tests.

For the precise calculation, let us set false-negative and false-positive rates of $P_{\text{fn}} = 0.2$ [9–11] and $P_{\text{fp}} = 0.05$ [1, 12] along with a prevalence (among the tested) of $q = 0.01$ and a pool size of $N = 8$ [1]. In this case the scheme’s false-negative rate is $P_{\text{sfn}} = 0.34$ and — a $E_{\text{rel}} = 70\%$ increase compared to $P_{\text{fn}} = 0.2$, the assumed test’s false-negative rate. Other combinations of values can be found in Figure 1.

4 Discussion

Although pooling improves testing throughput, we have shown that it can potentially increase false-negative rates. This result remains qualitatively similar under varying parameter values, in the observed ranges (refs) (Figure 1). The calculation in the beginning of Section 3, although simplistic in nature, does capture the crux of the matter: In every step there is some probability of a false-negative result, and these probabilities accumulate.

Although we have shown the inherent risk of Dorfman pooling, this shortcoming applies to other pooling schemes. Pooling schemes (e.g. [3, 13]), require some sequence of positive pooled results to correctly identify Donald as infected. Consider the pooling scheme of [13]: If the first pool yields a positive result, it is split in two. Then the splitting is repeated until resulting poolss are negative

or individuals are tested separately. With an initial pool size of 32, Donald will necessarily have to test positive in pools of size 32, 16, 8, 4 and 2, as well as in a single test, for the scheme to correctly identify him as infected. Compare this to the Dorfman scheme that requires a positive test in a pool of size $N = 8$, and an additional single positive test to identify Donald as infected. The pooling scheme of [13] will necessarily yield more false-negatives than Dorfman pooling — there are additional places for it to fail.

As mentioned in [1], introducing a positive dependence within a pool decreases the false-positive rate. In the extreme case, consider a fully connected pool, where one infection implies the entire pool is infected. In this case, a calculation analogous to the one conducted above recovers the initial false-negative rate P_{fn} . Interestingly, pooling was also noted to have increased throughput when infection probabilities are dependent between the pooled individuals [1], providing another advantage to sampling dependent individuals in pooling schemes.

To conclude, pooling is an important technique which can facilitate testing throughput in a cost-effective manner. Nevertheless, a substantial increase in pooling schemes’ false-negative rates can be expected. Such an increase in pooling schemes’ false-negative rates has crucial implications for controlling the spread of COVID-19.

References

- [1] Netta Barak, Roni Ben-Ami, Tal Sido, Amir Perri, Aviad Shtoyer, Mila Rivkin, Tamar Licht, Ayelet Peretz, Judith Magenheimer, Irit Fogel, et al., *Lessons from applied large-scale pooling of 133,816 SARS-CoV-2 RT-PCR tests*, MedRxiv (2020).
- [2] Robert Dorfman, *The detection of defective members of large populations*, The Annals of Mathematical Statistics **14** (1943), no. 4, 436–440.
- [3] US Food, Drug Administration, et al., *Accelerated emergency use authorization (eua) summary COVID-19 RT-PCR test (laboratory corporation of america)*.
- [4] Rudolf Hanel and Stefan Thurner, *Boosting test-efficiency by pooled testing strategies for SARS-CoV-2*, arXiv preprint arXiv:2003.09944 (2020).
- [5] Lauren M Kucirka, Stephen A Lauer, Oliver Laeyendecker, Denali Boon, and Justin Lessler, *Variation in false-negative rate of reverse transcriptase polymerase chain reaction—based SARS-CoV-2 tests by time since exposure*, Annals of Internal Medicine (2020).
- [6] Stefan Lohse, Thorsten Pfuhl, Barbara Berkó-Göttel, Jürgen Rissland, Tobias Geißler, Barbara Gärtner, Sören L Becker, Sophie Schneitler, and Sigrun Smola, *Pooling of samples for testing for SARS-CoV-2 in asymptomatic people*, The Lancet Infectious Diseases (2020).

- [7] Rodrigo Noriega and Matthew Samore, *Increasing testing throughput and case detection with a pooled-sample Bayesian approach in the context of COVID-19*, bioRxiv (2020).
- [8] Nikhil S Padhye, *Reconstructed diagnostic sensitivity and specificity of the RT-PCR test for COVID-19*, medRxiv (2020).
- [9] Jessica Watson, Penny F Whiting, and John E Brush, *Interpreting a COVID-19 test result*, BMJ **369** (2020).
- [10] L Wijsman, R Molenkamp, CBEM Reusken, A Meijer, et al., *Comparison of seven commercial RT-PCR diagnostic kits for COVID-19.*, Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology **128** (2020), 104412–104412.
- [11] Paul Wikramaratna, Robert S Paton, Mahan Ghafari, and Jose Lourenco, *Estimating false-negative detection rate of SARS-CoV-2 by RT-PCR*, medRxiv (2020).
- [12] Steven Woloshin, Neeraj Patel, and Aaron S Kesselheim, *False negative tests for SARS-CoV-2 infection — challenges and implications*, New England Journal of Medicine (2020).
- [13] Idan Yelin, Noga Aharony, Einat Shaer-Tamar, Amir Argoetti, Esther Messer, Dina Berenbaum, Einat Shafran, Areen Kuzli, Nagam Gandali, Tamar Hashimshony, et al., *Evaluation of COVID-19 RT-qPCR test in multi-sample pools*, MedRxiv (2020).